Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Current Deferred Revenue (2019 - 2025)

Silence Therapeutics (SLN) has disclosed Current Deferred Revenue for 7 consecutive years, with $168000.0 as the latest value for Q4 2025.

  • Quarterly Current Deferred Revenue fell 45.1% to $168000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $168000.0 through Dec 2025, down 45.1% year-over-year, with the annual reading at $168000.0 for FY2025, 45.1% down from the prior year.
  • Current Deferred Revenue hit $168000.0 in Q4 2025 for Silence Therapeutics, down from $301000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $10.4 million in Q4 2022 to a low of $168000.0 in Q4 2025.
  • Historically, Current Deferred Revenue has averaged $3.0 million across 5 years, with a median of $424500.0 in 2025.
  • Biggest five-year swings in Current Deferred Revenue: soared 81.6% in 2022 and later crashed 95.22% in 2024.
  • Year by year, Current Deferred Revenue stood at $5.7 million in 2021, then soared by 81.6% to $10.4 million in 2022, then plummeted by 38.39% to $6.4 million in 2023, then plummeted by 95.22% to $306000.0 in 2024, then tumbled by 45.1% to $168000.0 in 2025.
  • Business Quant data shows Current Deferred Revenue for SLN at $168000.0 in Q4 2025, $301000.0 in Q3 2025, and $457000.0 in Q2 2025.